Epigenetics of atopic dermatitis: pathogenesis and therapeutic prospects

IF 6.6 2区医学 Q1 IMMUNOLOGY

Current Opinion in Immunology Pub Date : 2025-05-31 DOI:10.1016/j.coi.2025.102581

Chi Fang , Pian Yu , Jie Li , Xiang Chen , Cong Peng

引用次数: 0

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease that poses a serious threat to human physical and mental health. Its main clinical features include itching, lichenification, and dry skin. The etiology of AD is not yet fully understood, and its pathogenesis is only partially elucidated. An increasing body of evidence suggests that this refractory disease is associated with epigenetic alterations, including specific modifications in immune cells and keratinocytes that play a key role in the pathogenesis of AD. The latest advances in epigenetic research have provided new insights into the pathogenesis of AD and potential therapeutic targets. In this review, we discuss the impact of DNA methylation, noncoding RNAs, and histone modifications on the pathogenesis of AD, emphasizing the potential of epigenetic modifications as targeted biomarkers, which pave the way for the development of novel targeted therapies and personalized medical approaches.

查看原文本刊更多论文

特应性皮炎的表观遗传学：发病机制和治疗前景

特应性皮炎（AD）是一种严重威胁人类身心健康的慢性炎症性皮肤病。其主要临床特征包括瘙痒、苔藓变和皮肤干燥。阿尔茨海默病的病因尚不完全清楚，其发病机制也只是部分阐明。越来越多的证据表明，这种难治性疾病与表观遗传改变有关，包括免疫细胞和角化细胞的特异性修饰，它们在AD的发病机制中起关键作用。表观遗传学研究的最新进展为阿尔茨海默病的发病机制和潜在的治疗靶点提供了新的见解。在这篇综述中，我们讨论了DNA甲基化、非编码rna和组蛋白修饰对AD发病机制的影响，强调了表观遗传修饰作为靶向生物标志物的潜力，这为开发新的靶向治疗和个性化医疗方法铺平了道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Immunology 医学-免疫学

CiteScore

13.30

自引率

1.40%

发文量

审稿时长

67 days

期刊介绍： Current Opinion in Immunology aims to stimulate scientifically grounded, interdisciplinary, multi-scale debate and exchange of ideas. It contains polished, concise and timely reviews and opinions, with particular emphasis on those articles published in the past two years. In addition to describing recent trends, the authors are encouraged to give their subjective opinion of the topics discussed. In Current Opinion in Immunology we help the reader by providing in a systematic manner: 1. The views of experts on current advances in their field in a clear and readable form. 2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications. Current Opinion in Immunology will serve as an invaluable source of information for researchers, lecturers, teachers, professionals, policy makers and students. Current Opinion in Immunology builds on Elsevier''s reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. It is a companion to the new Gold Open Access journal Current Research in Immunology and is part of the Current Opinion and Research(CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists'' workflow.